Form 4: BioXcel Therapeutics Executive Frank Yocca Reports Stock Sales and RSU Transactions
SEC Form 4
Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, reports the sale of common stock and the vesting of restricted stock units.
Summary
- On March 14, 2024, Frank Yocca exercised 521 Restricted Stock Units (RSUs) and sold 1,067 shares of common stock on April 4, 2024, at a weighted average price of $2.635 per share.
- These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 14, 2023.
- Following these transactions, Yocca directly owns 12,763 shares of BioXcel Therapeutics common stock and 4,169 RSUs from the March 14, 2022 grant and 6,750 RSUs from the March 15, 2023 grant.
- The RSUs vest in installments, contingent upon Yocca's continued employment with BioXcel Therapeutics.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment about the company's performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into insider transactions, allowing investors to monitor the buying and selling activities of company executives and directors.
Stakeholder Impact
- Shareholders can use this information to understand insider sentiment and potential motivations behind stock transactions.
Key Dates
| Date | Description |
|---|---|
| 2022-03-14 | Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter |
| 2023-03-15 | Reporting Person was granted 56,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter |
| 2023-12-14 | Rule 10b5-1 trading plan adopted |
| 2024-03-14 | 521 RSUs exercised |
| 2024-03-15 | 2,250 RSUs exercised |
| 2024-04-04 | 1,067 shares of common stock sold |
| 2024-04-08 | Date of Form 4 signature |
Keywords
BioXcel Therapeutics, BTAI, Form 4, Frank Yocca, Restricted Stock Units, RSU, Stock Sale, Rule 10b5-1, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.